'Merger Mania' Among Drug Firms Raises Concern About Commitment To Discovery

Commitment To Discovery Author: MYRNA E. WATANABE Junk bonds were the financial cause célèbre in the 1980s, but in the mid-'90s, the mega-merger-in media, banking, or pharmaceuticals-has taken center stage. Although it may be argued that all such deals revolve around the bottom line, profits, and increased stock prices, for drug companies, the directions they follow as a result of these monster corporate pairings take on an added dimension: Lives depend upon the drugs they manufacture.

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Commitment To Discovery Author: MYRNA E. WATANABE

Junk bonds were the financial cause célèbre in the 1980s, but in the mid-'90s, the mega-merger-in media, banking, or pharmaceuticals-has taken center stage. Although it may be argued that all such deals revolve around the bottom line, profits, and increased stock prices, for drug companies, the directions they follow as a result of these monster corporate pairings take on an added dimension: Lives depend upon the drugs they manufacture.

Venture capitalist Larry Bock, a general partner in Avalon Ventures in La Jolla, Calif., who has founded a dozen biotechnology firms, confirms that the aims of these major consolidations are not research-related, but rather "were done more for sales and marketing reasons" than for advancing the basic mission of the company.

Clinicians, researchers, and many in the general public fear that the current merger mania will see pharmaceutical firms cut research and development programs ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Myrna Watanabe

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio